Supernus Pharmaceuticals reported $149.59M in Gross Profit on Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Abbott ABT:US USD 5.78B 543M
Aerie Pharmaceuticals AERI:US USD 29.2M 370K
Ani Pharmaceuticals ANIP:US USD 50.93M 12.37M
Aurora Cannabis Inc ACB:CN CAD -22824000 580K
Bristol Myers Squibb BMY:US USD 8.86B 345M
Canopy Growth Corp WEED:CN CAD 3.82M 5.21M
Cara Therapeutics CARA:US USD 7.76M 15.24M
Corcept Therapeutics CORT:US USD 100.39M 1.68M
Eisai 4523:JP JPY 129.23B 7.63B
Eli Lilly And LLY:US USD 5.36B 305M
Endo International Ordinary Shares ENDP:US USD 364.83M 28.49M
Horizon Pharma HZNP:US USD 691.23M 45.03M
Lannett LCI:US USD 12.6M 4.74M
Marinus Pharmaceuticals MRNS:US USD 2.29M 502K
Pacira Pharmaceuticals PCRX:US USD 116.79M 2M
Perrigo Ordinary Shares PRGO:US USD 362.9M 9.2M
Pfizer PFE:US USD 16.55B 2.52B
Revance Therapeutics RVNC:US USD 18.28M 566K
Teva Pharmaceutical Industries TEVA:US USD 1.71B 118M
United Therapeutics UTHR:US USD 478.8M 41.6M
Xeris Pharmaceuticals Inc XERS:US USD 24.46M 3.97M